NCT07879469

Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2026-10-20Est. Completion: 2028-03-01

Enrollment target: 150 participants

Locations

The Second Hospital of Tianjin Medical University, Tianjin, China
Xingtai People's Hospital, Xingtai, China

Contact

Hailong Hu, MDhuhailong@tmu.edu.cn +8613662096232

Other microbiome trials you might be interested in

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney DysfunctionPhase 1Recruiting

Advanced Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaRecurrent Urothelial CarcinomaStage III Bladder Urothelial Carcinoma AJCC v6 and v7Stage IV Bladder Urothelial Carcinoma AJCC v7Unresectable Urothelial Carcinoma

This phase I/II trial studies the effect of eribulin mesylate and to see how well it works in treating patients with can…

Beverly Hills, United StatesEst. completion Jul 9, 2025

View Trial →

A Real-world Study to Learn About of the Characteristics and Outcomes of Advanced or Metastatic Bladder Cancer Patients With Different HistologiesRecruiting

Metastatic Urothelial Carcinoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.